ITM Power, a green hydrogen technology firm, reported a 68% rise in annual revenue to £43.6 million and reduced its adjusted EBITDA losses by 39% to £20.2 million for the year ending April 30. The company strengthened its market position with government support for new manufacturing capacity and a £40 million equity investment. ITM Power plans to use funding to develop next-gen electrolyser technology and launched Hydropulse to build and operate hydrogen plants, signing a major 150 MW project post-year-end. For the current year, it expects revenue between £50 million and £60 million and a reduced EBITDA loss of £17 million to £20 million.
ITM Power's financial update is presented here alongside Pluang's Energy sector data for context. For readers following energy stocks, as of Oct 19, 2026 14:31 WIB, 34 of 79 US energy stocks rose while 41 fell. Notable gainers include Imperial Oil Limited (IMO) at USD 133.92 with a 3.35% increase, Antero Resources Corporation (AR) at USD 37.85 up 3.33% with a typical hold time of 2 days, and Range Resources Corporation (RRC) at USD 43.22 rising 3.30%, also with a 2-day typical hold time.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
